Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 16/20 | 0.57 |
| ▸ | RAB9A | P51151 | 15/20 | 0.57 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887744 | 0.83 | NOTUM (0.51) | NPC1RAB9ATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL8471794 | 0.79 | NPC1 (0.60) | NPC1RAB9ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL4886294 | 0.77 | NPC1 (0.45) | NPC1RAB9ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL4888645 | 0.76 | GRM5 (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL4884701 | 0.75 | SMN1; SMN2 (0.41) | TSHRSMN1; SMN2HTTNPSR1TP53 | |
| SCHEMBL8900290 | 0.72 | NPC1 (0.68) | NPC1RAB9ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL334041 | 0.70 | NPC1 (0.68) | NPC1RAB9ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL18027882 | 0.68 | NPC1 (0.67) | NPC1RAB9ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL4885906 | 0.68 | NPC1 (0.53) | NPC1RAB9ATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL14153556 | 0.68 | RAB9A (0.51) | NPC1RAB9ATSHRKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-03-13 | — | — | US | disclosed |
| EP-1623983-A1 | Heterocyclic compounds useful as DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2006-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064728-A1 | Heterocyclic Compounds Useful as Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | NPC1 2114/4885RAB9A 2627/4885TSHR 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.